Clinical trial
A Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in Treatment of Coronary Artery Disease Patients: MeRes - China.
NCT03454724 is registered in ClinicalTrials.gov with Meril Life Sciences Pvt. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in Treatment of Coronary Artery Disease Patients: MeRes - China.
- Lead sponsor
- Meril Life Sciences Pvt. Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- January 1, 2020
- Completion date
- December 1, 2024
- Enrollment
- 484 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.